FENC
Fennec Pharmaceuticals Inc.
NASDAQ · USHealthcareBiotechnology
$9.90-5.71%
Price as of Jul 20, 2026
FENC financials
Fennec Pharmaceuticals Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $44.6M | $47.5M | $21.3M | $1.5M |
| Cost of revenue | $3.8M | $3.2M | $1.3M | $86.0K |
| Gross profit | $40.9M | $44.4M | $20.0M | $1.4M |
| Operating expenses | $47.2M | $41.9M | $33.1M | $24.2M |
| Operating income | -$6.3M | $2.5M | -$13.1M | -$22.7M |
| Net income | -$9.7M | -$436.0K | -$16.0M | -$23.7M |
| EBITDA | -$7.5M | $4.8M | -$12.4M | -$22.6M |
| Basic EPS | $-0.36 | $-0.02 | $-0.60 | $-0.95 |
| Diluted EPS | $-0.36 | $-0.02 | $-0.60 | $-0.95 |
| Balance sheet | ||||
| Cash & equivalents | $36.7M | $26.6M | $13.3M | $23.8M |
| Total assets | $70.1M | $44.9M | $26.9M | $26.9M |
| Total liabilities | $35.0M | $50.8M | $38.5M | $29.5M |
| Stockholders’ equity | $35.1M | -$5.9M | -$11.6M | -$2.6M |
| Total debt | $0.00 | $19.3M | $31.0M | $24.9M |
| Net debt | -$36.7M | -$7.3M | $17.7M | $1.1M |
| Cash flow | ||||
| Operating cash flow | -$12.5M | $27.0M | -$17.1M | -$18.1M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$12.5M | $27.0M | -$17.1M | -$18.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$176.0K | -$78.0K | -$194.0K |